Zonalon

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Zonalon

What is Zonalon

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a medication used to treat depression and anxiety. It works by blocking certain receptors in the brain that are linked to these conditions. Doxepin is a type of antidepressant known as a tricyclic, which means it shares properties with other drugs in its class like amitriptyline and desipramine. It was first developed by Pfizer and approved by the FDA in 1969 as an antidepressant. In 2010, it was also approved to treat insomnia.

Sinequan

is the brand name

image of different drug pills on a surface

Zonalon Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Zonalon Affects Patients

Doxepin is a type of antidepressant that works by decreasing the electrical activity of the brain. It can have effects such as making someone feel calmer and easing depression, but it can also make them feel sleepy. These effects usually take a few weeks to be fully felt, but the sedative effect is felt right away. High doses produce more noticeable side effects, like dizziness, confusion, and dry mouth.

How Zonalon works in the body

Doxepin works by blocking histamine receptors, which helps relieve skin conditions. It also works on the central nervous system to increase levels of norepinephrine and serotonin at synapse nerve terminals. This helps increase activity at post-synaptic neuron receptor sites and desensitizes serotonin 1A receptors and beta-adrenergic receptors. Finally, it increases dopamine levels in the frontal cortex, which helps improve its transmission in this area.

When to interrupt dosage

The prescribed measure of Zonalon depends on the recognized condition, including Depression, Involutional, Mental Disorder, Organic and Insomnia. The magnitude of dosage is contingent upon the method of delivery (e.g. Oral or Tablet - Oral) featured in the below table.

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

Zonalon has four potential contraindications and should not be utilized when any of the conditions specified in the following table are present.

Zonalon Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Zonalon.

Common Zonalon Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Zonalon Toxicity & Overdose Risk

Taking too much doxepin can cause seizures, abnormal heart rhythms, coma, low blood pressure, or even death. It has also been linked to reduced fertility in both males and females, including reduced number of viable embryos and lower sperm motility. There is no evidence to suggest that doxepin is carcinogenic or mutagenic.

image of a doctor in a lab doing drug, clinical research

Zonalon Novel Uses: Which Conditions Have a Clinical Trial Featuring Zonalon?

A vast 1020 active trials are being conducted to explore the potential of Zonalon in providing relief from Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

188 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

301 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

4 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Zonalon Reviews: What are patients saying about Zonalon?

5

Patient Review

11/30/2013

Zonalon for Itching

Over-the-counter itch creams and cold compresses failed to provide me with any relief from my neurodermatitis. This prescription, however, was very effective. I got instant relief but it made me drowsy.

5

Patient Review

9/7/2009

Zonalon for Skin Rash that Becomes Thick & Discolored From Rubbing It

Shoulder and hip pain has been a problem for me for a while, but after using this treatment, I get quick and long-lasting relief. I highly recommend it to anyone with similar issues.

4.7

Patient Review

2/1/2014

Zonalon for Skin Rash that Becomes Thick & Discolored From Rubbing It

Worked great for my severe pain from shingles, but I unfortunately developed an allergy to it. Now I'm on the lookout for a new treatment that can help me with the pain in my left armpit.

3

Patient Review

6/6/2010

Zonalon for Itching

The itching on my forearms has decreased with use, but now the skin is more red. I'll keep using it for now, but I'm also going to look for other options.

1

Patient Review

12/19/2008

Zonalon for Skin Rash that Becomes Thick & Discolored From Rubbing It

I've tried this medication for three weeks now and I haven't seen any results. In fact, I think I'm having an allergic reaction to it. My eyes are itching, my genitals are rashy, and I feel itchy all over.

1

Patient Review

9/17/2009

Zonalon for Itching

I don't think this would be effective for shingles.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zonalon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is doxepin and what are the side effects?

"Doxepin is a medication used to treat depression and anxiety by increasing the levels of certain natural substances in the brain. It is also available in tablet form to treat insomnia."

Answered by AI

Who makes Zonalon?

"Doxepin hydrochloride (equivalent to 4.4% doxepin) in a vehicle of sorbitol, cetyl alcohol, isopropyl myristate, glyceryl stearate, PEG-100 stearate, petrolatum, benzyl alcohol, titanium dioxide and purified water."

Answered by AI

What is the drug doxepin used for?

"Doxepin is a medication used to treat symptoms of anxiety or depression, as well as insomnia. It is classified as a tricyclic antidepressant (TCA), meaning it works by affecting the levels of certain chemicals in the brain."

Answered by AI

What is Zonalon cream used for?

"This medication is used to relieve itchiness from certain skin conditions such as eczema, neurodermatitis, and atopic dermatitis. However, it should only be used for a short amount of time not exceeding 8 days."

Answered by AI

Clinical Trials for Zonalon

Image of University of California, Los Angeles in Los Angeles, United States.

Digital Therapy for Postpartum Depression

18+
Female
Los Angeles, CA

The purpose of this study is to determine if the addition of digital sensing data collected from phones and watches during the early stages of perinatal depression (PND) treatment can better predict treatment outcomes than using self-reported symptoms alone.STAND for PND: The UCLA Depression Grand Challenge (DGC) has previously developed a technology-assisted, scalable therapy system called STAND (Screening and Treatment for ANxiety and Depression) for perinatal depression (PND) and has demonstrated in an initial randomized clinical trial that this treatment intervention to be as effective as psychiatrist delivered care for PND. In this study, the investigators will administer STAND for PND for up to 12 weeks as part of study participation. There will be no comparison between our treatment intervention and a treatment as usual condition, as this is not a trial of efficacy. In the STAND for PND treatment model, women with moderate symptoms will be routed to coach-guided, digital cognitive behavioral therapy (CBT) tailored to PND, which has been demonstrated to be an effective treatment approach for PND. Women with severe depression or suicidality will be routed to clinician delivered CBT, with pharmacotherapy as needed, with both CBT and pharmacotherapy demonstrated to be effective treatment approaches for PND. Symptoms will be regularly monitored throughout the intervention period. Digital Sensing in Depression: The DGC also has substantial experience in large-scale longitudinal digital sensing studies, and experience identifying associations between self-report or clinical ratings of depressive symptoms and digital sensing features, including in pregnant and postpartum women. Digital Sensing in a STAND for PND study: In our previous STAND for PND study, the investigators did not include digital sensing. In this next phase of our research program, the investigators will collect digital sensing data from phones and watches during the first four weeks of study participation. The investigators will enroll up to 250 women during their last trimester or who are in the postpartum period to participate in the 12-week study, which includes treatment provided through the STAND for PND program of care and during which the investigators will obtain 4-weeks of digital sensing data.The investigators will be testing whether behaviors measures through digital sensing (i.e., digital features) in combination with self-reported depression symptoms will better predict treatment outcomes than the self-reported depression symptoms alone. The investigators are testing the hypothesis that prospective longitudinal assessments using digital devices will enhance our ability to predict outcomes of STAND-PND.This project is part of a larger program of research that aims to improve clinical decision-making for PND by establishing a clinical care model for PND that fully integrates digital sensing with digital therapy. An additional objective of this program of research is to target low-income mothers from populations that have had limited access to mental healthcare, given that this population is particularly vulnerable to the impact of PND.

Waitlist Available
Has No Placebo

University of California, Los Angeles

Nelson Freimer, MD

Image of Imperial Valley College in Imperial, United States.

Cognitive Behavioral Therapy for Mental Health

18+
All Sexes
Imperial, CA

The goal of this study is to understand why certain treatments help people reduce repetitive negative thinking (RNT), which is common in many mental health problems. We want to: 1. Figure out what actually causes repetitive negative thinking to decrease when people use cognitive-behavioral therapy (CBT). 2. Find out which parts of RNT-focused CBT are the most important - the parts that truly make a difference in reducing RNT. The main result we will look at is how much a person's repetitive negative thought patterns change from the start of the study to the end of treatment (16 weeks). We will measure this using the Perseverative Thinking Questionnaire at baseline and week 16.

Waitlist Available
Has No Placebo

Imperial Valley College

Have you considered Zonalon clinical trials?

We made a collection of clinical trials featuring Zonalon, we think they might fit your search criteria.
Go to Trials
Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Waitlist Available
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Have you considered Zonalon clinical trials?

We made a collection of clinical trials featuring Zonalon, we think they might fit your search criteria.
Go to Trials
Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of Southern Methodist University in Dallas, United States.

Positive Affect Treatment for Depression and Anxiety

18 - 65
All Sexes
Dallas, TX

The purpose of this study is to evaluate the feasibility and acceptability of Positive Affect Treatment (PAT) in a Spanish-speaking population. PAT is a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low positive affect (a core feature of anhedonia) in the context of depression or anxiety. Target enrollment is 12 participants with low positive affect and depression or anxiety and impaired functioning, between the ages of 18 and 65 years. Participants will complete psychiatric assessments and self-report questionnaires as part of the study. The total length of participation is around 4 months.

Waitlist Available
Has No Placebo

Southern Methodist University

Alicia E Meuret, Ph.D.

Image of CVT in Centennial, United States.

Treatment for Depression

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Zonalon clinical trials?

We made a collection of clinical trials featuring Zonalon, we think they might fit your search criteria.
Go to Trials